Combined chemotherapy and radiotherapy assists low-grade glial brain tumours

In the April 7 issue of The New England Journal of Medicine, NRG Oncology researchers report the long-term results of this randomized clinical trial, which demonstrate that patients with grade 2 gliomas who received radiotherapy plus a chemotherapy regimen including procarbazine, lomustine (CCNU), and vincristine (PCV) experienced a longer progression-free survival and overall survival than those who received radiotherapy alone.